The data, from the SUMMIT and CREST phase II trial cohorts, suggest that the mechanism of bortezomib-induced thrombocytopenia varies from that of other cytotoxic agents and should be managed ...

GSK plc has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Blenrep. In the UK, ...